8-K
Current Report
Alaunos Therapeutics, Inc. Filed Acc 0000950170-21-001903
Exit or restructuring costs · Regulation FD disclosure
- Item 2.05 Costs associated with exit or disposal activities
- Item 7.01 Regulation FD disclosure
From the SEC's structured data for this filing
Loading ziop-20210927.htm…